B
Bull
Bull · 25%AZTR
$0.27
情境價格
$0.181
+0.004 (+2.43%)收盤時
Loading chart…
- High
- 0.183
- Open
- 0.171
- VWAP
- 0.18
- Vol
- 531.18K
- Mkt Cap
- 3.80M
- Low
- 0.169
- Amount
- 94.43K
- EV/EBITDA, TTM
- 0.00
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live bio therapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, chronic, xerotic (abnormally dry), and scaly skin disease.
AI analysis of Azitra Inc (AZTR)
holdAzitra Inc. (AZTR) is currently not a strong buy due to its high RSI of 74.12, indicating it may be overbought, and a significant year-to-date change of -36.53%, suggesting ongoing struggles despite recent gains.
估值指標
The current forward P/E ratio for Azitra Inc (AZTR) is 0.00, compared to its 5-year average forward P/E of -2.66.
Alphio AI Price Scenarios for AZTR
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
7.008-21PRnewswireAzitra Regains Compliance with NYSE American Listing Standards
7.008-21NewsfilterAzitra Regains Compliance with NYSE American Listing Standards
- 5.007-15Newsfilter
Azitra Reports Promising Anti-Wrinkle Results from Skin Studies
8.506-23NASDAQ.COMTenon Files S-1, Stock Surges 77.57%
- 8.506-16Newsfilter
Azitra to Showcase Pipeline Progress at BIO International Convention
AZTR FAQ — answered by Alphio AI
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live bio therapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, chronic, xerotic (abnormally dry), and scaly skin disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Azitra Inc. (AZTR) is currently not a strong buy due to its high RSI of 74.12, indicating it may be overbought, and a significant year-to-date change of -36.53%, suggesting ongoing struggles despite recent gains.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。